Your browser doesn't support javascript.
loading
Kaposi's sarcoma-associated herpesvirus replication and transcription activator protein activates CD274/PD-L1 gene promoter.
Miyazawa, Masanori; Yamamoto, Yuichiro; Katayama, Kazuhiro; Sugimoto, Yoshikazu; Noguchi, Kohji.
Afiliação
  • Miyazawa M; Division of Chemotherapy, Faculty of Pharmacy, Keio University, Tokyo, Japan.
  • Yamamoto Y; Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, Japan.
  • Katayama K; Division of Chemotherapy, Faculty of Pharmacy, Keio University, Tokyo, Japan.
  • Sugimoto Y; Laboratory of Molecular Targeted Therapeutics, School of Pharmacy, Nihon University, Chiba, Japan.
  • Noguchi K; Division of Chemotherapy, Faculty of Pharmacy, Keio University, Tokyo, Japan.
Cancer Sci ; 114(4): 1718-1728, 2023 Apr.
Article em En | MEDLINE | ID: mdl-36411531
ABSTRACT
Kaposi's sarcoma-associated herpesvirus (KSHV) is responsible for the pathogenesis of Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman disease. The expression of immunosuppressive genes, such as IL-10 and CD274/PD-L1 is observed during KSHV-associated pathogenesis, and the modulation of the host immune system by KSHV contributes to establishing viral persistence in the host. Understanding the mechanism that allows the virus to evade host cell immunity would be helpful in order to develop therapeutic strategies for KSHV malignancy. In this study, we show that KSHV replication and transcriptional activator (K-RTA), an essential activator of the viral lytic cycle, transactivates the CD274/PD-L1 gene promoter. Mechanistically, we demonstrate that the binding of K-RTA to the cellular specificity protein 1 (SP1) is critical for K-RTA-mediated CD274/PD-L1 promoter activation. These findings suggest that K-RTA cooperates with intracellular SP1 to activate the expression of CD274/PD-L1, which helps the virus regulate immune checkpoints to escape and survive.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Imediatamente Precoces / Herpesvirus Humano 8 Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Humans Idioma: En Revista: Cancer Sci Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Imediatamente Precoces / Herpesvirus Humano 8 Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Humans Idioma: En Revista: Cancer Sci Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão
...